BPC-157 is one of the most widely discussed research peptides, and also one of the most unevenly evidenced. A search returns hundreds of papers, but they are not equal: nearly all are animal or cell studies, and a large share come from one research network. The useful question is not "does the literature say it works?" but "what kinds of evidence exist, from what kinds of models, and how strong is each layer?" This article lays out that map. For compound background, see our BPC-157 overview.
The Molecule
BPC-157 ("body protection compound") is a synthetic pentadecapeptide, 15 amino acids long (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val), with a molecular weight of roughly 1.4 kDa. It is described in the literature as a fragment related to a protein found in human gastric juice, and it has been reported to be stable in gastric juice, which is unusual for a peptide and part of why the original work focused on the gut. It is a research compound and not an approved medicine.
Layer 1: What a 2025 Systematic Review Found
The most useful single reference is a systematic review in orthopaedic sports medicine by Vasireddi and colleagues (HSS Journal 2025;21(4):485-495). From 544 articles identified, 36 met inclusion criteria: 35 preclinical studies and one clinical study. The clinical study was a retrospective review of 12 patients receiving intra-articular BPC-157 for chronic knee pain, of whom 7 reported relief lasting more than six months. The authors concluded that preclinical muscle, tendon, ligament and bone models showed improved functional, structural and biomechanical outcomes, but that heterogeneity prevented a quantitative meta-analysis and that the absence of clinical outcome and safety data prevents evidence-based practice guidelines. They recommended caution. That summary is a fair description of the whole field and a good calibration point for everything below.
Layer 2: The Preclinical Models
- Tendon and ligament. Staresinic and colleagues reported accelerated healing of transected rat Achilles tendon and increased tendocyte growth in vitro (J Orthop Res 2003;21:976-983). Chang and colleagues reported that BPC-157 promoted tendon fibroblast outgrowth, survival and migration, with involvement of the FAK-paxillin pathway (J Appl Physiol 2011;110:774-780).
- Growth hormone receptor signaling. Chang and colleagues also reported that BPC-157 increased growth hormone receptor expression in tendon fibroblasts, via a JAK2-dependent pathway (Molecules 2014;19:19066-19077).
- Angiogenesis. Hsieh and colleagues reported pro-angiogenic effects associated with VEGFR2 activation and upregulation (J Mol Med 2017;95:323-333).
- Gut and the brain-gut axis. The original and largest body of work addresses gastrointestinal lesion models and interactions with the nitric-oxide system, summarized in review form (Sikiric et al., Curr Neuropharmacol 2016;14:857-865).
- Musculoskeletal soft tissue. A narrative review by Gwyer, Wragg and Wilson summarized the pathways and the animal data on soft-tissue healing (Cell Tissue Res 2019;377:153-159).
Layer 3: Human Data
The human evidence is the thin layer: the small retrospective knee-pain study identified in the 2025 review, plus very limited early-phase clinical activity that has not produced published efficacy or safety trials. No randomized, controlled human trial of efficacy has been reported in the peer-reviewed literature as of the 2025 review.
How Strong Is the Evidence, Honestly?
| Question | State of evidence |
|---|---|
| Do animal tendon/muscle models show faster healing with BPC-157? | Consistently reported across multiple studies; heterogeneous design |
| Is there a plausible cellular mechanism? | Proposed (FAK-paxillin, GH receptor/JAK2, VEGFR2, NO system); not fully independently confirmed |
| Is it effective in humans? | Not established; no controlled trials |
| Is it safe in humans? | Not established; no clinical safety data |
Known Weaknesses of the Literature
- Concentration of authorship. A large fraction of studies come from one research group, which limits independent replication.
- Heterogeneity. Routes, doses, injury models and outcome measures vary widely.
- Pharmacokinetics. The 2025 review notes a short half-life (under 30 minutes) and hepatic metabolism with renal clearance, which makes the reported durable effects from brief exposure a point that needs mechanistic explanation.
- Publication patterns. Positive findings dominate, as is common in preclinical fields.
Regulatory Context
BPC-157 has no approved medical use. It is listed among substances prohibited by the World Anti-Doping Agency as a non-approved substance, and FDA has placed it in a category of bulk substances raising significant safety questions for compounding. Check current agency positions, which change.
Sources
- Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J 2025;21(4):485-495. doi:10.1177/15563316251355551. PMC
- Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res 2003;21:976-983.
- Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol 2011;110:774-780.
- Chang CH, et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules 2014;19:19066-19077.
- Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med 2017;95:323-333.
- Sikiric P, et al. Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications. Curr Neuropharmacol 2016;14:857-865.
- Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res 2019;377:153-159.
For research use only. Not for human or veterinary consumption. This article is educational and describes published literature; it makes no claims about the use of any product.